Clinical Trials Search

Official Title: A Prospective Randomized Pivotal Trial of the FARAPULSE Pulsed Field Ablation System Compared With Standard of Care Ablation in Patients With Paroxysmal Atrial Fibrillation

Study Purpose: This is a prospective, adaptive, multi-center, randomized safety and effectiveness pivotal study comparing the FARAPULSE Pulsed Field Ablation System with standard of care ablation with force-sensing RF catheters and cryoballoon catheters indicated for the treatment of PAF.

Status: Active, Not Recruiting

Official Title: A Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-ANG3 in Adults With Mixed Dyslipidemia

Study Purpose: The purpose of AROANG3-2001 is to evaluate the efficacy and safety of ARO-ANG3 in participants with mixed dyslipidemia. Participants will receive 2 subcutaneous injections of ARO-ANG3 or placebo.

Status: Active, Not Recruiting

Official Title: A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia

Study Purpose: The purpose of AROAPOC3-2001 is to evaluate the efficacy and safety of ARO-APOC3 in participants with severe hypertriglyceridemia. Participants will receive 2 subcutaneous injections of ARO-APOC3.

Status: Recruiting

Official Title: BOLT: A Prospective, Multicenter Study of Patients with Deep Vein Thrombosis to Evaluate the Safety and Efficacy of the Indigo® Aspiration System

Study Purpose: Evaluated Safety and Efficacy of Indigo Aspiration System

Status: Recruiting

Official Title: A randomized trial of ultrasound-facilitated, catheter-directed, thrombolysis versus anticoagulation for acute intermediate-high risk pulmonary embolism: The higher-risk pulmonary embolism thrombolysis study.

Study Purpose: To assess whether ultrasound-facilitated, catheter-directed, thrombolysis and anticoagulation are associated with a significant reduction in the composite outcome of pulmonary embolism (PE)-related mortality, cardiorespiratory decompensation or collapse, or nonfatal symptomatic and objectively confirmed recurrence of PE compared to anticoagulation alone within seven days of randomization.

Status: Recruiting

Official Title: Assessment of Wound Closure Comparing Synthetic Hybrid- Scale Fiber Matrix with Lyophilized Acellular Fish Skin in Treating Diabetic Foot Ulcers (DFU) and with Living Cellular Skin Substitute in Treating Venous Leg Ulcers (VLU)

Study Purpose: The purpose of the following prospective study is to compare synthetic hybrid-scale fiber matrix with lyophilized acellular fish skin in treating diabetic foot ulcers in human subjects, and to compare synthetic hybrid-scale fiber matrix with living cellular skin substitute in treating venous leg ulcers.

Status: Recruiting

Official Title: Stimulation Of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in Non-Responders and Previously Untreatable Patients (SOLVE CRT)

Study Purpose: This study is a prospective, multi-center, randomized, controlled, double blinded, pivotal trial to study the safety and efficacy of the WiSE-CRT System for Cardiac Re-synchronization Therapy.

Status: Recruiting

Official Title: A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes (STRIDE)

Study Purpose: This study is done to see if semaglutide has an effect on walking ability compared with placebo in people with peripheral arterial disease (PAD) and type 2 diabetes.

Status: Recruiting

Official Title: A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease (VICTORION-2 PREVENT)

Study Purpose: The purpose of this phase III study is to test the effectiveness of inclisiran sodium 300 mg in addition to well-tolerated high-intensity statin therapy in participants with established cardiovascular disease in reducing cardiovascular events including death, non-fatal MI, and non-fatal stroke.

Status: Recruiting

Official Title: Effects of ziltivekimab versus placebo on cardiovascular outcomes in patients with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation.

Study Purpose: An interventional, randomised, parallel-group, double-blind, placebo-controlled, multi-centre, multi-national CVOT designed to evaluate the effects of 15 mg ziltivekimab versus placebo (randomised 1:1), both administered s.c. once-monthly and added to standard of care, on CV outcomes in participants with established ASCVD, CKD and systemic inflammation.

Status: Recruiting